Previous 10 | Next 10 |
SELLAS Life Sciences Group (NASDAQ: SLS ) has closed its public offering of 26,367,200 common shares and warrants to purchase same number of common shares and 73,632,800 pre-funded warrants. More news on: SELLAS Life Sciences Group, Inc., Healthcare stocks news, Stocks on the move, R...
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of indications, today ann...
NEW YORK, June 14, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indication...
NPS-Specific Cytotoxic T-Lymphocyte Mean Frequencies Increased by 2.86-fold Compared to Baseline at 30 months Notable Correlation Between Progressive Increase of NPS-Specific Cytotoxic T-Lymphocyte in NPS Plus Trastuzumab Patient Cohort and Remaining Clinically Relapse-Free Over Time ...
SELLAS Life Sciences (NASDAQ: SLS ): Q1 GAAP EPS of -$0.22 beats by $0.01 . More news on: SELLAS Life Sciences Group, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, to...
Memorial Sloan Kettering Cancer Center will conduct an open-label Phase 1 clinical trial evaluating the combination of SELLAS Life Sciences' ( SLS +4% ) galinpepimut-S (GPS) and Bristol-Myers Squibb's ( BMY -0.2% ) Opdivo (nivolumab) in patients with malignant pleural mesothelioma...
Initiation of Phase 1 Clinical Trial in Relapsed or Refractory MPM Expected in the Second Quarter of 2019 Previous Combination Study of GPS and Nivolumab Given After Salvage Chemotherapy in Ovarian Cancer Patients Showed 1-year Progression-Free Survival Rate of 70% and Induction of ...
SELLAS Life Sciences (NASDAQ: SLS ): FY GAAP EPS of -$4.82. More news on: SELLAS Life Sciences Group, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications,...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...